TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$24.65 USD
-0.63 (-2.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $24.64 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 1 - 20 ( 278 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
2Q24 Results; Strong Briumvi Sales; Full Year Guidance Raised Again
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
1Q24 Results; Strong Briumvi Sales Beat Expectations; Raising PT to $49
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
National Contract With the Department of Veterans Affairs For Briumvi as Preferred Anti-CD20 for RMS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Phase 3b ENHANCE Study Data Presented at ACTRIMS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
4Q23 Results; 2024 Guidance Unchanged; Exceptional Briumvi Sales Growth Expected in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
International Partner, Neuraxpharm, Launches Briumvi in Germany, Triggering $12.5M Milestone Payment
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Preliminary 4Q23 and FY23 U.S. Briuvmi Sales Ahead of Estimates; Raising 2024 Revenue Estimate and Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Global License Agreement With Precision BioSciences For Precision''s Allogeneic CD19 CAR T Program in Autoimmune Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Optimized Entry and Exit Levels for TGTX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: TG Therapeutics, Inc.
Industry: Medical - Products
3Q23 Results; Briumvi Sales Exceed Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Highlights From Fireside Chat With TG Therapeutics
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
2Q23 Results; Briumvi OUS Marketing Deal Announced; U.S. Sales Double Sequentially and Beat Our Estimate
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Briumvi Receives Approval From the European Commission For the Treatment of Adults With RMS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Data From ULTIMATE I and II Trials to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
1Q23 Results; Initial Briumvi Sales Exceed Expectations; Raising PT by $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Positive CHMP Opinion For Briumvi For the Treatment of Relapsing Forms of Multiple Sclerosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Planned ULTIMATE I & II Data Presentations Announced For the American Academy of Neurology (AAN) Annual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E